Dependence of CD8+ T-cell-mediated suppression of HIV type 1 on viral phenotypes and mediation of phenotype-dependent suppression by viral envelope gene and not by β-chemokines

AIDS Research and Human Retroviruses

Volumn 16, Issue 2, 2000, Pages 117-124

  Chen, Yue ^a   Dampf, Deena ^a   Chen, Meisheng ^a   Kulka, Kathy ^a   Volsky, David J ^b   Saha, Kunal ^b   Gupta, Phalguni ^a,c  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CHEMOKINE; VIRUS ENVELOPE PROTEIN;

ARTICLE; CELLULAR IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE FUNCTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS INHIBITION; VIRUS REPLICATION;

CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINES, CC; COHORT STUDIES; CYTOTOXICITY, IMMUNOLOGIC; GIANT CELLS; HIV-1; HUMANS; PHENOTYPE; T-LYMPHOCYTES, CYTOTOXIC; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

EID: 0033978654     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200309467     Document Type: Article

References (50)

1. 1. Munoz A, Want M, Bass S, Taylor M, Kingsley L, Chmiel J, Folk B, and the Multicenter AIDS Cohort Study: Acquired immunodeficiency syndrome (AIDS) free time after human immunodeficiency virus type 1 (HIV-1) seroconversion in homosexual men. Am J Epidemiol 1989;130:530-539.
2. 2. Levy J: Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 1993;57:183-289.
3. 3. Mellors JW, Kingsley LA, Rinaldo CR Jr, Todd JA, Hoo BS, Kokka RP, and Gupta P: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122: 573-579.
4. 4. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, and Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-1170.
5. 5. McMichael A and Walker B: Cytotoxic T lymphocyte epitopes: Implications for HIV vaccines. AIDS 1994;8:S155-S173.
6. 6. Rinaldo CR Jr, Beltz LA, Huang XL, Gupta P, Fan Z, and Torpey DJ III: Anti-HIV type 1 cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men. AIDS Res Human Retroviruses 1995;11: 481-489.
7. 7. Rinaldo C, Huang XL, Fan Z, Ding M, Beltz L, Logar A, Panicali D, Mazzara G, Liebmann J, Cottrill M, and Gupta P: High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 1995;69:5838-5842.
8. + T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodeficiency virus-specific cytotoxicity. Proc Natl Acad Sci USA 1990;87:4818-4822.
9. 9. Walker B, Chakrabart S, Moss B, Paradis T, Flynn T, Durno A, Blumberg R, Kaplan R, Hirsch M, and Schooley R: HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature (London) 1997;328:345-348.
10. 10. Walker C, Moody D, and Stiles D: CD8 lymphocytes can control HIV infection by suppressing virus replication. Science 1986; 234:1563-1566.
11. + T lymphocytes suppresses HIV replication. Immunology 1989;66:628-630.
12. + cells involves a noncytotoxic mechanism. J Virol 1991;65: 5921-5927.
13. + T cells from HIV-1 infected individuals inhibit acute infection by human and primate immunodeficiency viruses. Cell Immunol 1991;137:420-428.
14. + lymphocyte activity. J Infect Dis 1995;172:329-339.
15. 15. Ferbas J, Navratil J, Logar A, and Rinaldo C: Selective decrease in human immunodeficiency virus type 1 (HIV-1)-induced alpha interferon production by peripheral blood mononuclear cells during HIV-1 infection. Clin Diag Lab Immunol 1995;2:138-142.
16. + T cells. J Immunol 1990;140:2237-2242.
17. + T cells. Immunol Today 1996;17:217-224.
18. + T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc Natl Acad Sci USA 1995;92:2308-2312.
19. + T lymphocyte mediated inhibition of HIV-1 long terminal repeat transcription: A novel antiviral mechanism. AIDS Res Hum Retroviruses 1993;9:1079-1086.
20. + T cells is not lentivirus specific. AIDS Res Hum Retroviruses 1995;11:1321-1326.
21. + cell antiviral factor. Cell Immunol 1994;153:329-343.
22. + T cells. Science 1995;270:1811-1815.
23. 23. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwarz O, Heard JM, dark-Lewis I, Legier DF, Loetscher M, Baggiolini M, and Moser B: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature (London) 1996; 382:833-835.
24. 24. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, and Springer TA: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature (London) 1996;382:829-832.
25. 25. Pal R, Garzino-Demo A, Markham PD, Burns J, Brown M, Gallo RC, and DeVico AL: Inhibition of HIV-1 infection by the β-chemokine MDC. Science 1997;278:695-698.
26. + T-cell mediated suppression of HIV-1 infection may not be due to chemokines RANTES, MIP1 and MIP-1. AIDS 1996;10:1434-1436.
27. + T cell clone. AIDS 1996;10:1317-1321.
28. 28. Clerici M, Balotta C, Trabaltoni D, Pappagno L, Ruzzante S, Rusconi S, Fusi M, Colombo M, and Galli M: Chemokine production in HIV-seropositive long term asymptomatic individuals. AIDS 1996;10:1432-1433.
29. 29. Mackewicz C, Barker E, and Levy J: Role of chemokines in suppressing HIV replication. Science 1996;274:1393-1394.
30. + T cell suppression of syncytia-inducing strains of HIV-1. Proc Natl Acad Sci USA 1997;94:9842-9847.
31. 31. Godiska R, Chantry D, Raport CJ, Sozzani S, Allavena P, Leviten D, Mantovani A, and Gray PW: Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J Exp Med 1991;185:1595-1604.
32. + cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 1991;87:1462-1466.
33. + cell response against human immunodeficiency virus: Implications for long term survival. Proc Natl Acad Sci USA 1995;92:11135-11139.
34. + T cell mediated suppression of HIV-1 infection. Clin Diagn Lab Immunol 1996;4:4-10.
35. 35. Peden K, Emerman M, and Montagnier L: Charges in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1. Virology 1991;185:661-672.
36. + T-cell clones from PBLs of HIV-1 infected subjects using herpesvirus saimiri. Nat Med 1996;2:1272-1275.
37. 37. Mittrucker H, Muller-Fleckenstein I, Fleckenstein B, and Fleischer B: Herpesvirus saimiri-transformed human T lymphocytes: Normal functional phenotype and preserved T cell receptor signaling. Int Immunol 1993;5:985-990.
38. 38. Meinl E, Hohfeld R, Wekerle H, and Fleckenstein B: Immortalization of human T cells by herpesvirus saimiri. Immunol Today 1995;16:55-58.
39. 39. Chen M, Singh M, and Gupta P: Isolation of two infectious molecular clones of HIV-1 with divergent biologic property longitudinally isolated from a seropositive subject. AIDS Res Hum Retroviruses 1997;13:743-750.
40. 40. Chen M and Gupta P: Co-operative interaction of V1-V2 region with V3 region of HIV-1 gp120 is important for productive viral infection: Its role in binding of gp120 to viral co-receptor. Paper number 28 in 5th Conference on Retroviruses and Opportunistic Infections, 1998.
41. 41. Deng H, Lu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Marzio P, Marmon S, Sutton R, Hill M, Davis C, Peiper S, Schall T, Littman D, and Landan N: Identification of a major co-receptor for primary isolates of HIV-1. Nature (London) 1996;381:661-666.
42. 3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med 1996;2:1244-1247.
43. + cell anti-HIV activity: Nonlytic suppression of virus replication. AIDS Res Hum Retroviruses 1992;8:1039-1050.
44. 44. Cheng-Mayer C, Ouiroga M, Tung J, Dina D, and Levy J: Viral determinants of human immunodeficiency virus type 1 T cell/ macrophage tropism, cytopathogenicity and CD4 antigen modulation. J Virol 1990;64:4390-4398.
45. 45. Shioda T, Levy JA, and Cheng-Mayer C: Macrophage and T-cell tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature (London) 1991;349:167-169.
46. 46. Tersmette M, Gruters R, de Wolf F, de Goede R, Lange J, Schellekens P, Goudsmit J, Huisman H, and Miedema F: Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: Studies on sequential HIV isolates. J Virol 1989;63:2118-2125.
47. + T cell phenotype correlates with anti-HIV-activity and asymptomatic clinical status. Clin Immunol Immunopathol 1993;69:106-116.
48. + cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-688.
49. 49. Koot M, Schellekens P, Mulder J, Lange J, Roos M, Coutinko R, Tersmette M, and Miedema F: Viral phenotype and T cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine. J Infect Dis 1993;168:733-736.
50. 50. Schuitemaker H, Koot M, Kootstra N, Dercksen M, de Goede R, van Steenwijk R, Lang J, Schattenkerk J, Miedema F, and Tersmette M: Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J Virol 1992;66:1354-1360.